Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -7% Improvement Relative Risk ICU admission 57% ARDS 28% Hospitalization time 31% no CI Hospitalization time (b) 73% c19vitamind.com Torres et al. Vitamin D for COVID-19 RCT LATE TREATMENT Favors vitamin D Favors control
Torres, 85 patient vitamin D late treatment RCT: 28% lower ARDS [p=0.74] and 31% lower hospitalization https://c19p.org/torres
copied to clipboard
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D
Torres et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112965
14 Apr 2022    Source   PDF   Share   Tweet
RCT comparing 41 patients treated with 10,000IU/day cholecalciferol and 44 treated with 2,000IU/day in Spain, showing significantly shorter hospitalization for ARDS patients with the higher dose. There was also an increase of anti-inflammatory cytokine IL-10 and higher levels of CD4+ T cells. Cytotoxic response against pseudotyped SARS-CoV-2 infected cells was over 4-fold higher in patients receiving the higher dose.
risk of death, 7.3% higher, RR 1.07, p = 1.00, treatment 1 of 41 (2.4%), control 1 of 44 (2.3%).
risk of ICU admission, 57.1% lower, RR 0.43, p = 0.44, treatment 2 of 41 (4.9%), control 5 of 44 (11.4%), NNT 15.
risk of ARDS, 28.5% lower, RR 0.72, p = 0.74, treatment 4 of 41 (9.8%), control 6 of 44 (13.6%), NNT 26.
hospitalization time, 31.2% lower, relative time 0.69, treatment 41, control 44.
hospitalization time, 72.6% lower, relative time 0.27, p = 0.04, ARDS patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Torres et al., 4/14/2022, Single Blind Randomized Controlled Trial, Spain, Europe, peer-reviewed, median age 65.0, 51 authors, study period June 2020 - March 2021, dosage 10,000IU days 1-14.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit